Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01840085 · ClinicalTrials.gov registry record · Phase 3
Open-Label Study in Diabetic Foot Ulcers (DFU), to Evaluate Safety of 0.03% DSC127 Topical Gel in Chronic Use
A Phase 3 study, sponsored by Integra LifeSciences Corporation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 261
- Enrollment target
NCT01840085 is a Phase 3 study that was terminated before completion, run by Integra LifeSciences Corporation. The registered enrollment target is 261 participants.
The verdict
NCT01840085, a Phase 3 study, was terminated before completion, sponsored by Integra LifeSciences Corporation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 261 participants
- Enrollment target
Study Summary
To evaluate the safety of topical 0.03% DSC127 Gel when used for one or more continuous treatment periods on a chronic Wagner Grade 1 or 2 foot ulcer(target ulcer) or multiple ulcers in diabetic subjects. The maximum duration of any treatment period is 24 weeks.
Interventions
- DRUG 0.03% DSC127 topical gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 261 participants |
| Start Date | 2015-12 |
| Est. Completion | 2015-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01840085
The ClinicalTrials.gov registry entry for NCT01840085 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 261 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Integra LifeSciences Corporation, which has 60 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 0.03% DSC127 topical gel is the first listed.
NCT01840085 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01840085 about?
NCT01840085 is a clinical study titled "Open-Label Study in Diabetic Foot Ulcers (DFU), to Evaluate Safety of 0.03% DSC127 Topical Gel in Chronic Use". To evaluate the safety of topical 0.03% DSC127 Gel when used for one or more continuous treatment periods on a chronic Wagner Grade 1 or 2 foot ulcer(target ulcer) or multiple ulcers in diabetic subjects. The maximum duration of any treatment period is 24 weeks.
What is the current status of trial NCT01840085?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 261 participants. The study started on 2015-12. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01840085?
The interventions under investigation include: 0.03% DSC127 topical gel (DRUG).
Who is sponsoring clinical trial NCT01840085?
This trial is sponsored by Integra LifeSciences Corporation, which has 60 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.